Table 3.
Continuation rates and reasons for discontinuation.
| Discontinuation Due to | ||||||
|---|---|---|---|---|---|---|
| Authors & Year | Continuation Rate | Expulsion | Pain | Unacceptable Bleeding | Pregnancy Wish/Personal reasons | Other |
| Pakarinen et al. 1996 [41] | 86.9% at 1st year | |||||
| Suhonen et al. 2004 [45] | 79.8% at 1st year | 1.1% | 6.4% | 2.1% | 4.2% | Hormonal: 4.2% Other medical: 2.1% |
| Wildemeersch et al. 2005 [51] | 90.2% at 1st year | 1.1% | 2.2% | 2.2% | 3.2% | Other: 1.1% |
| Bahamondes et al. 2011 [32] | 92.0% at 1st year | 3.7% | 1.5% | 2.4% | Other medical: 0.8% Lost to follow-up: 1.6% |
|
| Marions et al. 2011 [39] | 73.1% at 1st year | 3.0% | 11.9% | 10.4% | Infection/cyst: 1.5% | |
| Armitage et al. 2013 [31] | 77.3% at 1st year | 2.1% | 4.1% | 2.1% | Lost to follow up: 10.3% Others: 4.1% |
|
| Savasi et al. 2014 [43] | 92.6%-different observation time | 1.9% | 1.9% | 5.6% | ||
| Zhao et al. 2014 [52] | 90.0% at 1st year | |||||
| Abraham et al. 2015 [30] | Younger than 20: 81.0% at 1st year 67.0% at 2nd year 20–25 years old: 87.0% at 1st year 79.0% at 2nd year Older than 25: 87.0% at 1st year 77.0% at 2nd year |
|||||
| Kaislasuo et al. 2015 [37] | 73.0% at 1st year | 2.7% | 1.8% | Other: 6.3% Lost to follow-up: 16.2% |
||
| Gemzell-Danielsson et al. 2015 [35] | LNG-IUS 8: 78.8% at 1st year 54.3% at 2nd year LNG-IUS 13: 79.8% at 1st year 58.1% at 2nd year |
|||||
| Hall et al. 2016 [36] | 93.1% at 1st year | 1.4% | Side effects: 4.2% Lack of benefit: 1.4% |
|||
| Wildemeersch et al. 2017 [49] | 53.8% at 5th year | 0% | 6.0% | 29.9% | Other medical: 6.8% Lost to follow up: 2.6% Pregnancy: 0.9% |
|
| Vaitsiakhovich et al. 2018 [48] | In RCT: 74.0% at 1st year 70.0% at 2nd year |
|||||
| Teunissen et al. 2019 [47] | 76.8% at 1st year 63.6% at 2nd year 50.4% at 3rd year 37.5% at 4th year 11.1% at 5th year |
|||||
Abbreviations: LNG-IUS: levonorgestrel-releasing intrauterine system; RCT: randomized controlled trial.